We are live on
!
Find out more
Two Sigma Advisers Portfolio holdings
AUM
$51.4B
1-Year Est. Return
31.07%
This Fund
S&P 500
This Quarter
Est. Return
-16.56%
1 Year Est. Return
+31.07%
3 Year Est. Return
+128.94%
5 Year Est. Return
+161.75%
10 Year Est. Return
+607.04%
AUM
$35.3B
AUM Growth
-$2.37B
(-6.3%)
Cap. Flow
+$5.08B
Cap. Flow
% of AUM
14.42%
Top 10 Holdings %
Top 10 Hldgs %
12.79%
Holding
3,021
New
306
Increased
1,176
Reduced
1,104
Closed
398
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$410M |
| 2 |
Snap
SNAP
|
+$321M |
| 3 |
Altria Group
MO
|
+$312M |
| 4 |
Meta Platforms (Facebook)
META
|
+$295M |
| 5 |
Intel
INTC
|
+$283M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CERN
Cerner Corp
CERN
|
+$407M |
| 2 |
AbbVie
ABBV
|
+$283M |
| 3 |
S&P Global
SPGI
|
+$251M |
| 4 |
Amazon
AMZN
|
+$221M |
| 5 |
Eli Lilly
LLY
|
+$197M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.06% |
| 2 | Healthcare | 18.6% |
| 3 | Financials | 10.47% |
| 4 | Industrials | 10.2% |
| 5 | Consumer Discretionary | 7.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
Taysha Gene Therapies
TSHA
$1.54B
| $394K | ﹤0.01% |
105,800
-30,500
| -22% | -$121K |
|
|
EXK
2027
Endeavour Silver
EXK
$2.23B
| $393K | ﹤0.01% |
125,100
+111,700
| +834% | +$441K |
|
2028
ASE Group
ASX
$72.9B
| $391K | ﹤0.01% |
+75,600
| New | +$504K |
|
2029
Scansource
SCSC
$1.15B
| $391K | ﹤0.01% |
12,563
-5,600
| -31% | -$196K |
|
|
SMED
2030
DELISTED
Sharps Compliance Corp
SMED
| $391K | ﹤0.01% |
133,800
-12,600
| -9% | -$52.6K |
|
|
PLM
2031
DELISTED
PolyMet Mining Corp.
PLM
| $391K | ﹤0.01% |
142,210
+102,000
| +254% | +$315K |
|
2032
Kinsale Capital Group
KNSL
$8.59B
| $390K | ﹤0.01% |
+1,700
| New | +$376K |
|
|
SOHU
2033
Sohu.com
SOHU
$351M
| $388K | ﹤0.01% |
23,400
-28,700
| -55% | -$448K |
|
2034
Innovative Industrial Properties
IIPR
$1.79B
| $385K | ﹤0.01% |
3,500
+1,700
| +94% | +$241K |
|
2035
Nuvation Bio
NUVB
$2.28B
| $385K | ﹤0.01% |
118,700
+97,000
| +447% | +$423K |
|
2036
KLA
KLAC
$247B
| $383K | ﹤0.01% |
12,000
-29,000
| -71% | -$975K |
|
2037
VSE Corp
VSEC
$5.47B
| $383K | ﹤0.01% |
+10,200
| New | +$400K |
|
2038
Westwater Resources
WWR
$49.4M
| $382K | ﹤0.01% |
353,400
-113,600
| -24% | -$148K |
|
2039
Bank First Corp
BFC
$1.69B
| $379K | ﹤0.01% |
5,000
+700
| +16% | +$50.4K |
|
2040
Escalade
ESCA
$266M
| $379K | ﹤0.01% |
+29,201
| New | +$382K |
|
2041
Zymeworks
ZYME
$1.65B
| $379K | ﹤0.01% |
71,600
-232,700
| -76% | -$1.41M |
|
2042
CTS Corp
CTS
$1.85B
| $378K | ﹤0.01% |
11,100
+5,100
| +85% | +$185K |
|
2043
Clear Secure
YOU
$5.3B
| $378K | ﹤0.01% |
+18,900
| New | +$510K |
|
|
DCBO
2044
Docebo
DCBO
$524M
| $376K | ﹤0.01% |
+13,100
| New | +$497K |
|
2045
Matthews International
MATW
$892M
| $376K | ﹤0.01% |
+13,100
| New | +$400K |
|
2046
Rackspace Technology
RXT
$917M
| $376K | ﹤0.01% |
52,500
+18,600
| +55% | +$168K |
|
2047
Adaptive Biotechnologies
ADPT
$3.54B
| $375K | ﹤0.01% |
46,400
+34,300
| +283% | +$302K |
|
2048
BridgeBio Pharma
BBIO
$16.4B
| $375K | ﹤0.01% |
41,280
+13,800
| +50% | +$115K |
|
2049
Northwest Bancshares
NWBI
$2.36B
| $375K | ﹤0.01% |
+29,300
| New | +$373K |
|
|
MSB
2050
Mesabi Trust
MSB
$303M
| $373K | ﹤0.01% |
15,200
-4,500
| -23% | -$117K |
|
Similar funds
CWM
VRS
FAF
BGIM
CIM
PPFA
Two Sigma Advisers's Q2 2022 Portfolio in Review
As of Q2 2022, Two Sigma Advisers held 3,021 positions worth $35.3B, down 6.3% from $37.6B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Two Sigma Advisers deployed $5.08B of net new capital in Q2 2022, opening 306 new positions and adding to 1,176 existing holdings. Its largest new stake was Snap: 14,064,077 shares worth $185M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was AbbVie, an estimated $283M trimmed.
- Two Sigma Advisers's largest Q2 2022 buy was Snap: 14,064,077 shares worth $185M.
- Two Sigma Advisers added most to Netflix in Q2 2022, an estimated $410M increase.
- Two Sigma Advisers's biggest Q2 2022 reduction was AbbVie, cutting an estimated $283M.
- Two Sigma Advisers fully exited Cerner Corp in Q2 2022, selling an estimated $407M.
- Two Sigma Advisers's ten largest holdings make up 13% of its $35.3B portfolio in Q2 2022.
- Two Sigma Advisers opened 306 new positions and closed 398 in Q2 2022.
- Two Sigma Advisers's portfolio value fell 6.3% quarter-over-quarter to $35.3B.
Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.